Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
暂无分享,去创建一个
[1] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[2] J. Buse,et al. Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes , 2005 .
[3] B. Staels,et al. Therapeutic roles of peroxisome proliferator-activated receptor agonists. , 2005, Diabetes.
[4] I. Campbell. The Clinical Significance of PPAR Gamma Agonism. , 2005, Current molecular medicine.
[5] Alfonso T. Perez,et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. , 2005, Diabetes care.
[6] Weiqi Wang,et al. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities. , 2005, Journal of medicinal chemistry.
[7] C. Long,et al. PPAR-γ activation fails to provide myocardial protection in ischemia and reperfusion in pigs , 2005 .
[8] C. Long,et al. PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. , 2005, American journal of physiology. Heart and circulatory physiology.
[9] J. Buse,et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. , 2005, Clinical therapeutics.
[10] T. Elasy,et al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: a consensus statement from the American Heart Association and American Diabetes Association Response to Nesto , 2004 .
[11] J P Riveline,et al. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. , 2003, Diabetes & metabolism.
[12] Kieran Clarke,et al. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. , 2003, Cardiovascular research.
[13] J. Mehta,et al. Peroxisome Proliferator-Activated Receptor Ligands as Antiatherogenic Agents: Panacea or Another Pandora's Box? , 2002, Journal of cardiovascular pharmacology and therapeutics.
[14] Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.
[15] Ames,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[16] J. Vamecq,et al. Medical significance of peroxisome proliferator-activated receptors , 1999, The Lancet.
[17] J. Auwerx,et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. , 1995, The Journal of clinical investigation.
[18] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.